Ergomed plc Total Voting Rights (0288V)
03 Abril 2023 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 0288V
Ergomed plc
03 April 2023
Total Voting Rights
Guildford, UK - 3 April 2023 : In accordance with the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
("DTRs"), Ergomed plc (the "Company") announces the following
information.
The Company's issued share capital as at 31 March 2023 consisted
of 50,776,805 ordinary shares of 1p each, none of which were held
in treasury. Each ordinary share in the capital of the Company
carries one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company, under the DTRs.
ENDS
Enquiries :
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets and
Strategy)
Numis (Nominated Advisor and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRJBMRTMTMJBBJ
(END) Dow Jones Newswires
April 03, 2023 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024